• Recruiting

NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM

Updated: Sep 24

NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma

REGN5458

The primary objective of the study is to assess the safety and tolerability, and identify the recommended dose of REGN5458 for the expansion portion in combination with each one of the following cancer treatments:


Daratumumab plus dexamethasone (Dd: Cohort 1)

Carfilzomib plus dexamethasone (Kd: Cohort 2)

Lenalidomide plus dexamethasone (Rd: Cohort 3)

Bortezomib plus dexamethasone Vd: (Cohort 4)


Sponsor

Regeneron Pharmaceuticals

 

ClinicalTrials.gov Identifier: NCT05137054

Official Title: Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma

First Posted: November 30, 2021

Click here for details on ClinicalTrials.gov

 

REGN-5458

Linvoseltamab (Code C158504)

Anti-BCMA x Anti-CD3 BiTE REGN5458

Anti-BCMA/CD3 BiTE Antibody REGN5458

Bispecific BCMA x CD3 T-cell Engaging Antibody REGN5458

BiTE Antibody REGN5458

Linvoseltamab

LINVOSELTAMAB

REGN 5458

REGN-5458

REGN5458

 

Drug: REGN5458

Drug: Daratumumab

Drug: Carfilzomib

Drug: Lenalidomide

Drug: Bortezomib

Drug: Dexamethasone

 

Locations

Europe

Spain

 

Related Posts


NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)

Click here for details


NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM

Click here for details


NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM

Click here for details

Posts Archive